Last updated on February 2018

Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR


Brief description of study

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following allogeneic SCT in first CR, after either myeloablative (MAC) or reduced intensity (RIC) conditioning, will also be evaluated. With an adaptative design, this clinical trial could test up to 3 novel AML agents of interest.

Clinical Study Identifier: NCT02416388

Find a site near you

Start Over

H pitaux de Brabois_CHU Nancy

Vandoeuvre-les-Nancy, France
  Connect »

CHU Estaing

Clermont-Ferrand, France
  Connect »

CH Victor Dupouy

Argenteuil, France
  Connect »

CH Lens

Lens, France
  Connect »

CHU Angers

Angers, France
  Connect »

CH Beziers

Beziers, France
  Connect »

CH Bordeaux

Bordeaux, France
  Connect »

H pital du Dr Duchenne

Boulogne sur Mer, France
  Connect »

CH Caen

Caen, France
  Connect »

Clinique du parc

Castelnau Le lez, France
  Connect »

HIA Percy

Clamart, France
  Connect »

CH Dunkerque

Dunkerque, France
  Connect »

CH Versailles

Le Chesnay, France
  Connect »

CH Meaux

Meaux, France
  Connect »

H pital Saint Eloi

Montpellier, France
  Connect »

CH Mulhouse

Mulhouse, France
  Connect »

IUCT Toulouse

Toulouse, France
  Connect »

CH Valenciennes

Valenciennes, France
  Connect »